Cargando…
A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
Ovarian low-grade serous carcinoma (LGSC) and high-grade serous carcinoma have distinct molecular profiles, clinical behaviors, and treatment responses. The survival advantage for patients with low-grade carcinoma compared with patients with high-grade histology remains controversial. We retrospecti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206388/ https://www.ncbi.nlm.nih.gov/pubmed/25342912 http://dx.doi.org/10.2147/OTT.S67812 |
_version_ | 1782340814553219072 |
---|---|
author | Chen, Ming Jin, Ying Bi, Yalan Yin, Jie Wang, Yongxue Pan, Lingya |
author_facet | Chen, Ming Jin, Ying Bi, Yalan Yin, Jie Wang, Yongxue Pan, Lingya |
author_sort | Chen, Ming |
collection | PubMed |
description | Ovarian low-grade serous carcinoma (LGSC) and high-grade serous carcinoma have distinct molecular profiles, clinical behaviors, and treatment responses. The survival advantage for patients with low-grade carcinoma compared with patients with high-grade histology remains controversial. We retrospectively reviewed the medical charts of 381 patients with ovarian serous carcinoma at Peking Union Medical College Hospital from 2007 to 2010. Patients were classified into two groups according to MD Anderson two-tier system: 35 (9.2%) cases with LGSC and 346 with high-grade serous carcinoma. Patients with low-grade serous ovarian cancer had a significantly younger age at diagnosis (46 versus 56 years, P=0.046), and their median progression-free survival (PFS) and overall survival values were 35.0 and 54.0 months, respectively. A multivariate analysis showed that, for serous ovarian cancer, the histological grade was a significant prognostic factor for PFS but not for overall survival (P=0.022 and P=0.0566, respectively). When stratified by the existence of a residual disease, patients with low-grade disease who underwent cytoreductive surgery without macroscopic residual disease (>1 cm) had a significantly improved median PFS time (36.0 months) compared with that of patients with high-grade carcinoma who received optimal cytoreductive surgery (16.0 months, P=0.017). Conversely, patients with low-grade and high-grade carcinoma who were left with macroscopic residue (>1 cm) experienced a similarly shorter median PFS (10.0 and 13.0 months, respectively, P=0.871). The International Federation of Gynecology and Obstetrics stage and residual disease were significant prognostic factors of low-grade carcinoma, while positive ascites was associated with a worse PFS value. Our data showed that LGSC is a different entity from high-grade carcinoma and that LGSC was associated with improved PFS after optimal cytoreductive surgery but not suboptimal operation. |
format | Online Article Text |
id | pubmed-4206388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-42063882014-10-23 A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology Chen, Ming Jin, Ying Bi, Yalan Yin, Jie Wang, Yongxue Pan, Lingya Onco Targets Ther Original Research Ovarian low-grade serous carcinoma (LGSC) and high-grade serous carcinoma have distinct molecular profiles, clinical behaviors, and treatment responses. The survival advantage for patients with low-grade carcinoma compared with patients with high-grade histology remains controversial. We retrospectively reviewed the medical charts of 381 patients with ovarian serous carcinoma at Peking Union Medical College Hospital from 2007 to 2010. Patients were classified into two groups according to MD Anderson two-tier system: 35 (9.2%) cases with LGSC and 346 with high-grade serous carcinoma. Patients with low-grade serous ovarian cancer had a significantly younger age at diagnosis (46 versus 56 years, P=0.046), and their median progression-free survival (PFS) and overall survival values were 35.0 and 54.0 months, respectively. A multivariate analysis showed that, for serous ovarian cancer, the histological grade was a significant prognostic factor for PFS but not for overall survival (P=0.022 and P=0.0566, respectively). When stratified by the existence of a residual disease, patients with low-grade disease who underwent cytoreductive surgery without macroscopic residual disease (>1 cm) had a significantly improved median PFS time (36.0 months) compared with that of patients with high-grade carcinoma who received optimal cytoreductive surgery (16.0 months, P=0.017). Conversely, patients with low-grade and high-grade carcinoma who were left with macroscopic residue (>1 cm) experienced a similarly shorter median PFS (10.0 and 13.0 months, respectively, P=0.871). The International Federation of Gynecology and Obstetrics stage and residual disease were significant prognostic factors of low-grade carcinoma, while positive ascites was associated with a worse PFS value. Our data showed that LGSC is a different entity from high-grade carcinoma and that LGSC was associated with improved PFS after optimal cytoreductive surgery but not suboptimal operation. Dove Medical Press 2014-10-16 /pmc/articles/PMC4206388/ /pubmed/25342912 http://dx.doi.org/10.2147/OTT.S67812 Text en © 2014 Chen et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Chen, Ming Jin, Ying Bi, Yalan Yin, Jie Wang, Yongxue Pan, Lingya A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
title | A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
title_full | A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
title_fullStr | A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
title_full_unstemmed | A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
title_short | A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
title_sort | survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206388/ https://www.ncbi.nlm.nih.gov/pubmed/25342912 http://dx.doi.org/10.2147/OTT.S67812 |
work_keys_str_mv | AT chenming asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT jinying asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT biyalan asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT yinjie asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT wangyongxue asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT panlingya asurvivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT chenming survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT jinying survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT biyalan survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT yinjie survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT wangyongxue survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology AT panlingya survivalanalysiscomparingwomenwithovarianlowgradeserouscarcinomatothosewithhighgradehistology |